Hrain anti-BCMA CAR-T vs HRC0202

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

Hrain anti-BCMA CAR-T

Developed by Hrain Biotechnology Co., Ltd.

Phase 2 in Multiple Myelomacell therapy (autologous BCMA-targeted CAR-T)
Weak signal

NCT03093168 · Phase 1 · status unknown

This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The published five-year analysis reports 49 treated patients, more than this study's originally listed enrollment.

Reported efficacy

Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0 (6 months): ORR 77.55% (38/49 patients); sCR 24.49% (12 patients), CR 24.49% (12 patients); median PFS 9.5 months (95% CI 5.01-13.99), median OS 20.0 months (95% CI 11.26-28.74)

Result source: NCT03093168

HRC0202

Developed by Hrain Biotechnology Co., Ltd.

Phase 2 in Multiple MyelomaCAR-T (autologous, BCMA-directed)
Weak signal

NCT04003168 · Phase 1 · status unknown

This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The published report covers seven treated patients, fewer than the study's listed enrollment.

Reported efficacy

Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0 (28 days post infusion): In seven patients with relapsed/refractory multiple myeloma previously treated with anti-BCMA CAR-T (four relapsed, three refractory), the best overall response rate was 71.4% (5/7), with stringent complete response or complete response achieved in three patients. Cytokine release syndrome of grades 1-2 occurred in three patients (42.9%) and grade >=3 in two patients (28.6%).

Result source: NCT04003168

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHrain anti-BCMA CAR-THRC0202
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

Hrain anti-BCMA CAR-T
—Not reported
HRC0202
—Not reported

OS, median

Hrain anti-BCMA CAR-T
—Not reported
HRC0202
—Not reported

ORR

Hrain anti-BCMA CAR-T
—Not reported
HRC0202
—Not reported

VGPR or better

Hrain anti-BCMA CAR-T
—Not reported
HRC0202
—Not reported

MRD negativity

Hrain anti-BCMA CAR-T
—Not reported
HRC0202
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Hrain anti-BCMA CAR-T: no structured comparison results are available for Multiple Myeloma.

HRC0202: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hrain anti-BCMA CAR-T's landscape · HRC0202's landscape